Eric Schmidt

Stock Analyst at Cantor Fitzgerald

(0.82)
# 3,829
Out of 4,893 analysts
48
Total ratings
25%
Success rate
-14.22%
Average return

Stocks Rated by Eric Schmidt

Avidity Biosciences
Jun 27, 2025
Reiterates: Overweight
Price Target: $96
Current: $31.45
Upside: +205.25%
Prothena Corporation
Jun 20, 2025
Reiterates: Neutral
Price Target: n/a
Current: $6.57
Upside: -
Cidara Therapeutics
Jun 10, 2025
Reiterates: Overweight
Price Target: n/a
Current: $50.95
Upside: -
Summit Therapeutics
Apr 23, 2025
Reiterates: Overweight
Price Target: n/a
Current: $25.88
Upside: -
Immatics
Apr 1, 2025
Reiterates: Overweight
Price Target: n/a
Current: $6.01
Upside: -
Alumis
Mar 20, 2025
Reiterates: Overweight
Price Target: n/a
Current: $3.56
Upside: -
Bicara Therapeutics
Mar 13, 2025
Reiterates: Overweight
Price Target: $13
Current: $9.94
Upside: +30.89%
ADC Therapeutics
Mar 7, 2025
Reiterates: Overweight
Price Target: n/a
Current: $3.30
Upside: -
CRISPR Therapeutics AG
Feb 19, 2025
Reiterates: Neutral
Price Target: n/a
Current: $59.00
Upside: -
Incyte
Jan 10, 2025
Reiterates: Neutral
Price Target: n/a
Current: $70.33
Upside: -
Reiterates: Overweight
Price Target: n/a
Current: $39.57
Upside: -
Reiterates: Overweight
Price Target: n/a
Current: $6.10
Upside: -
Reiterates: Overweight
Price Target: n/a
Current: $35.45
Upside: -
Reiterates: Overweight
Price Target: $292
Current: $135.33
Upside: +115.77%
Reiterates: Overweight
Price Target: $370
Current: $479.53
Upside: -22.84%
Downgrades: Neutral
Price Target: n/a
Current: $3.06
Upside: -
Initiates: Outperform
Price Target: n/a
Current: $0.42
Upside: -